Some Ohioans who suffer from epileptic seizures may find that, due to their specific medical conditions, their remedies are few and far between. Their seizures could be so debilitating and frequent to significantly impact their quality of life. However, some sufferers of epileptic seizures may soon find more relief as a new medical marijuana drug has been approved by the federal government for the treatment of two specific epilepsy conditions.
In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has issued its first approval for a cannabis-based drug. The drug, Epidiolex, has been thoroughly studied and submitted to clinical trials. Therefore, the FDA is able to regulate the drug, and it will be available via prescription starting this fall.
Epidiolex can be prescribed to treat two types of epilepsy conditions. One of these is the genetic condition Dravet syndrome. The other condition is Lennox-Gastaut syndrome. The FDA commissioner has stated that this is an “important medical advance.” The company that manufactures the drug has also touted the medication, stating it is the first drug made with plant-based cannabinoid that can treat epilepsy without causing a “high.”
This is significant, as it is now legal for doctors to prescribe a specific cannabis-based drug that is safe, regulated and non-synthetic. It can be prescribed to patients in all states, not just those that permit the manufacturing, sale and use of medical marijuana. While it may only be prescribed for the two aforementioned epilepsy conditions, this advance in medical marijuana means more people will have access to these drugs without fear of being charged with a drug crime.